ArticleJACC. Advances2026
Coronary Plaque Burden in South Asian Adults: Insights From the DILWALE Registry.
Article in JACC. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSouth Asian (SA) adults have disproportionately high rates of premature coronary artery disease, yet conventional risk calculators may not fully capture coronary plaque burden.
objectivesWe analyzed the DILWALE (DIL Wellness and Arterial Health Longitudinal Evaluation) registry to quantify coronary plaque burden using computed tomography angiography (CTA) and compare it across risk categories using the 10-year atherosclerotic cardiovascular disease (ASCVD) risk calculator and American Heart Association PREVENT-ASCVD Calculator.
methodsThe DILWALE study is a medical record-based multicenter registry of SA adults (≥18 years) within Baylor Scott & White Health system. Patients who underwent clinically indicated coronary CTA were included and were risk stratified based on the PREVENT-ASCVD and Pooled Cohort Equations (PCE) risk scores. Quantitative plaque analysis was done using HeartFlow's plaque analysis tool to evaluate the association among PCE, PREVENT, and plaque burden.
resultsA total of 341 SAs were included. Among individuals stratified by the PREVENT score, median total plaque volume rose from 0 mm
conclusionsIn this SA cohort, higher PREVENT and ASCVD/PCE risk categories were associated with higher plaque burden. CTA reveals substantial noncalcified plaque missed by calcium scoring, underscoring its value for anatomic risk in SA adults.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.